Cantor Fitzgerald Keeps Their Buy Rating on Cidara Therapeutics (CDTX)

By Jason Carr

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Cidara Therapeutics (CDTXResearch Report) today and set a price target of $15. The company’s shares opened today at $2.84.

Chen noted:

“CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15.”

According to, Chen is a 5-star analyst with an average return of 11.2% and a 43.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cidara Therapeutics with a $12 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.35 and a one-year low of $1.94. Currently, Cidara Therapeutics has an average volume of 83.09K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.